Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk.
Among patients with atrial fibrillation at intermediate risk for stroke, DOAC therapy led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes at 24 months than no anticoagulation.